RE: https://mstdn.ca/@ducky/116780751613938974

Some notable things from @ducky 's weekly roundup https://covidbc.webfoot.com/2026/06/19/2026-06-19-general/ :

for children over 8 years old, ones with a history of reinfection were almost ten times more likely to get Long COVID than those who did not. For children under 8 y/o, reinfection doubled the risk, and boys were almost five times more likely to get Long COVID than girls.

and

that one dose of an mRNA COVID-19 vaccine reduced the likelihood of developing Long COVID by 63%.

More evidence for metformin's effectiveness against LC, and first I've heard of sodium-glucose cotransporter-2 inhibitors (SGLT2i) having an impact as well.

#SARSCoV2 #COVID19 #COVID #LongCOVID #metformin

· Two recent studies added more evidence that diabetes drug #Metformin can reduce risk of #LongCOVID
[https://link.springer.com/article/10.1007/s40121-026-01362-z | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag335/8702406]
· Long COVID disproportionately impacts Indigenous people in California
[https://www.researchsquare.com/article/rs-9452333/v1]
· 2020 diagnostic consensus on #MCAS (which can get triggered by #COVID) enabled diagnosis & improved treatment of the condition
[https://www.degruyterbrill.com/document/doi/10.1515/dx-2026-0016/html]

https://thesicktimes.org/2026/06/16/research-updates-june-16/

#ResearchUpdates #TheSickTimes

Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study - Infectious Diseases and Therapy

Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.

SpringerLink

Enttäuschender Medizinjournalismus

Medizinportale berichten von einer Studie, laut der bei #COVID19 eingenommenes #Metformin das Risiko, an #LongCovid halbiere.

Tatsächlich zeigte die Studie, die einige Probleme hat, leider keine signifikante Wirkung. Lediglich ein sekundärer Endpunkt ("klinisch diagnostiziertes Long Covid") war positiv, allerdings mit einem enorm hohen Konfidenzintervall - risk ratio 0.495 (95% CrI 0.155 to 0.995).

Vielleicht werden zukünftige Studien ein Wirksamkeit von Metformin belegen. Hinweise dafür gibt es ja einige. Aber wenn Studienergebnisse so selektiv wiedergegeben werden, ohne auf den Unterschied primärer vs sekundärer Endpunkt oder auf Konfidenzintervalle einzugehen, dann ist das Ahnungslosigkeit oder Propaganda.

Die Studie:
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag335/8702406?login=false

Started taking #Metformin last week. No appetite and I hadn’t noticed.

I ended up throwing food away as it was out of date.

That was the only sign I had that anything was different.

RE: https://disabled.social/@tomkindlon/116717085328668673

This study used a self-report for primary outcome, and found

Some secondary outcomes did have high posterior probabilities of efficacy, including 0.98 for symptom burden on day 120 and 0.96 for clinician diagnosis of long COVID on day 180.

So I think the real result from this study is "the study was underpowered" and not "metformin doesn't work for LC" because their results also cannot be distinguished from "metformin during acute COVID-19 reduces Long COVID rate by a quarter"

People who got Metformin:

  • were 24% less likely to self-report Long COVID at 180 days
  • were 22% less likely to be clinically diagnosed with Long COVID at 180 days

and consider their conclusion:

Metformin did not exceed the primary outcome threshold for declaring efficacy for reducing PASC. The posterior probability of efficacy for metformin was high for preventing a clinician diagnosis of long COVID and for symptom burden, consistent with prior clinical trial and observational data. No safety concerns occurred in this trial of metformin in low-risk adults. While a low event rate makes it challenging to evaluate therapeutics

https://dx.doi.org/10.1093/cid/ciag335

#COVID #COVID19 #SARSCoV2 #LongCOVID #Metformin #PASC

Metformin, the diabetes drug that has been thought to suppress glucose production in the liver, instead inhibits mitochondria in the gut, causing the gut to increase its consumption (and breakdown) of glucose.

Summary: https://refractor.io/diabetes/metformin-gut-health-benefits/

Original paper: https://www.nature.com/articles/s42255-026-01530-y

#Science #Metformin #Diabetes #Metabolism

Diabetes 'wonder drug' doesn't work like expected – but it's good news

It's long been thought that the type-2 diabetes drug taken by an estimated 20 million Americans was doing its heavy lifting in the liver, suppressing the production of glucose to regulate blood sugar. But new research has uncovered it's actually working its magic in the gut – which opens the door…

Refractor

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

📰 Original title: Diabetes Drug, Metformin, May Echo the Benefits of Exercise in Prostate Cancer Care

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

View full AI summary: https://killbait.com/en/metformin-raises-exercise-associated-metabolite-lac-phe-in-prostate-cancer-patients-on-hormone-therapy/?redirpost=e646279c-9669-4f2b-83ba-fba5b2643fac

#health #metformin #prostate...

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

A new study from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that the common diabetes drug metformin can increase levels of N-lactoyl-phenylalanine…

KillBait Archive

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

📰 Original title: Diabetes Drug, Metformin, May Echo the Benefits of Exercise in Prostate Cancer Care

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

View full AI summary: https://killbait.com/en/metformin-raises-exercise-associated-metabolite-lac-phe-in-prostate-cancer-patients-on-hormone-therapy/?redirpost=e646279c-9669-4f2b-83ba-fba5b2643fac

#health #metformin #prostate...

Metformin Raises Exercise-Associated Metabolite Lac-Phe in Prostate Cancer Patients on Hormone Therapy

A new study from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that the common diabetes drug metformin can increase levels of N-lactoyl-phenylalanine…

KillBait Archive

After 60+ years, the common diabetes drug metformin has been found to unexpectedly affect the brain.
A new study shows it targets the protein Rap1 in the ventromedial hypothalamus, activating SF1 neurons to help lower blood glucose — and it works at much lower concentrations in the brain than in the body.
Promising findings that could lead to better treatments for glucose control and possibly brain protection.

#Metformin #Diabetes #BrainHealth #MedicalResearch #Prediabetes

https://www.sciencealert.com/after-60-years-diabetes-drug-revealed-to-unexpectedly-affect-the-brain

After 60 Years, Diabetes Drug Revealed to Unexpectedly Affect The Brain

Metformin has been prescribed to people with type 2 diabetes to manage blood sugar for more than 60 years, but scientists haven't been exactly sure how it works - until now.

ScienceAlert
Researchers at Baylor College of Medicine published a study in Science Advances today revealing that metformin targets the Rap1 protein in the brain's ventromedial hypothalamus to lower blood sugar, overturning 60 years of medical consensus. #Science #Metformin #Health #Medicine #Research
https://blazetrends.com/metformin-brain-discovery-scientists-shatter-60-year-diabetes-consensus-with-new-rap1-protein-study/?fsp_sid=204728
Metformin brain discovery: Scientists shatter 60-year diabetes consensus with new Rap1 protein study

Shutterstock

Blaze Trends